Movatterモバイル変換


[0]ホーム

URL:


SG11201806340YA - Zika virus vaccine - Google Patents

Zika virus vaccine

Info

Publication number
SG11201806340YA
SG11201806340YASG11201806340YASG11201806340YASG11201806340YASG 11201806340Y ASG11201806340Y ASG 11201806340YASG 11201806340Y ASG11201806340Y ASG 11201806340YASG 11201806340Y ASG11201806340Y ASG 11201806340YASG 11201806340Y ASG11201806340Y ASG 11201806340YA
Authority
SG
Singapore
Prior art keywords
international
nucleic acid
polypeptides
artificial nucleic
rule
Prior art date
Application number
SG11201806340YA
Inventor
Benjamin Petsch
Edith Jasny
Yves Girerd-Chambaz
Original Assignee
Curevac Ag
Sanofi Pasteur Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Curevac Ag, Sanofi Pasteur SafiledCriticalCurevac Ag
Publication of SG11201806340YApublicationCriticalpatent/SG11201806340YA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property -, Organization 111111110111101110101011111010111110111010111011011110111111101111101111011111 International Bureau 0.. .1 j ..... ..or::,„, (10) International Publication Number (43) International Publication Date WO 2017/140905 Al 24 August 2017 (24.08.2017) WI P0 I P CT (51) International Patent Classification: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, A61K 39/12 (2006.01) HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, (21) International Application Number: MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, PCT/EP2017/053721 NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (22) International Filing Date: RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, 17 February 2017 (17.02.2017) TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (25) Filing Language: English (84) Designated States (unless otherwise indicated, for every (26) Publication Language: English kind of regional protection available): ARIPO (BW, GH, (30) Priority Data: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, PCT/EP2016/053398 TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, 17 February 2016 (17.02.2016) EP TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, (71) Applicants: CUREVAC AG [DE/DE]; Paul-Ehrlich-Str. LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, 15, 72076 Tiibingen (DE). SANOFI PASTEUR SA SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, [FR/FR]; 2, avenue Pont Pasteur, 69367 Lyon Cedex 07 GW, KM, ML, MR, NE, SN, TD, TG). (FR). Declarations under Rule 4.17: (72) Inventors: PETSCH, Benjamin; Hagellocher Weg 44, — of inventorship (Rule 4.17(N)) 72070 Tiibingen (DE). JASNY, Edith; Dorfstr. 70, 72074 Tiibingen (DE). GIRERD-CHAMBAZ, Yves; 22, chemin Published: de la Pra, 69510 Messimy (FR). — with international search report (Art. 21(3)) (74) Agents: VON STOSCH, Andreas et al.; Prinzregentenstr. before limit the expiration of the time for amending the 22, 80538 Munich (DE). claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (81) Designated States (unless otherwise indicated, for every kind AE, AG, AL, AM, of national protection available): _ with sequence listing part of description (Rule 5.2(a)) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, Il ir) 0 01 0 ll• 1-1 (54) Title: ZIKA VIRUS VACCINE I N (57) : The present invention is directed to an artificial nucleic acid and to polypeptides suitable for use in treatment or pro - 11 O phylaxis of an infection with Zika virus or a disorder related to such an infection. In particular, the present invention concerns a Zika N virus vaccine. The present invention is directed to an artificial nucleic acid, polypeptides, compositions and vaccines comprising the O artificial nucleic acid or the polypeptides. The invention further concerns a method of treating or preventing a disorder or a disease, ,-t first and second medical uses of the artificial nucleic acid, polypeptides, compositions and vaccines. Further, the invention is direc - .,. ted to a kit, particularly to a kit of parts, comprising the artificial nucleic acid, polypeptides, compositions and vaccines.
SG11201806340YA2016-02-172017-02-17Zika virus vaccineSG11201806340YA (en)

Applications Claiming Priority (2)

Application NumberPriority DateFiling DateTitle
EP20160533982016-02-17
PCT/EP2017/053721WO2017140905A1 (en)2016-02-172017-02-17Zika virus vaccine

Publications (1)

Publication NumberPublication Date
SG11201806340YAtrue SG11201806340YA (en)2018-09-27

Family

ID=55398295

Family Applications (2)

Application NumberTitlePriority DateFiling Date
SG10201913630YASG10201913630YA (en)2016-02-172017-02-17Zika virus vaccine
SG11201806340YASG11201806340YA (en)2016-02-172017-02-17Zika virus vaccine

Family Applications Before (1)

Application NumberTitlePriority DateFiling Date
SG10201913630YASG10201913630YA (en)2016-02-172017-02-17Zika virus vaccine

Country Status (6)

CountryLink
US (2)US11723967B2 (en)
EP (1)EP3416683A1 (en)
BR (1)BR112018016755A2 (en)
MX (2)MX2018009917A (en)
SG (2)SG10201913630YA (en)
WO (1)WO2017140905A1 (en)

Families Citing this family (93)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
WO2012019630A1 (en)2010-08-132012-02-16Curevac GmbhNucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012116714A1 (en)2011-03-022012-09-07Curevac GmbhVaccination in elderly patients
WO2013120499A1 (en)2012-02-152013-08-22Curevac GmbhNucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
CA2897858A1 (en)2013-02-222014-08-28Curevac GmbhCombination of vaccination and inhibition of the pd-1 pathway
SG11201510746WA (en)2013-08-212016-03-30Curevac AgRespiratory syncytial virus (rsv) vaccine
AU2014310935B2 (en)2013-08-212019-11-21CureVac SECombination vaccine
CA2915712A1 (en)2013-08-212015-02-26Margit SCHNEERabies vaccine
EP3116535B1 (en)2014-03-122019-08-07CureVac AGCombination of vaccination and ox40 agonists
IL289934B2 (en)2014-06-252023-04-01Acuitas Therapeutics IncNovel lipids and lipid nanoparticle formulations for delivery of nucleic acids
EP3708668B1 (en)2014-12-122022-07-27CureVac AGArtificial nucleic acid molecules for improved protein expression
AU2016253972B2 (en)2015-04-272020-01-02Acuitas Therapeutics Inc.Nucleoside-modified RNA for inducing an adaptive immune response
WO2016180430A1 (en)2015-05-082016-11-17Curevac AgMethod for producing rna
DE202016009003U1 (en)2015-05-292021-05-28Curevac Real Estate Gmbh Composition comprising in vitro transcribed RNA obtainable by a method for the production and purification of RNA with at least one step with a tangential flow filtration
PL3313829T3 (en)2015-06-292024-08-19Acuitas Therapeutics Inc.Lipids and lipid nanoparticle formulations for delivery of nucleic acids
US11364292B2 (en)2015-07-212022-06-21Modernatx, Inc.CHIKV RNA vaccines
ES2937963T3 (en)2015-07-212023-04-03Modernatx Inc Infectious disease vaccines
WO2017064146A1 (en)2015-10-122017-04-20Curevac AgAutomated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
EP3364950A4 (en)2015-10-222019-10-23ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
HUE061564T2 (en)2015-10-282023-07-28Acuitas Therapeutics Inc New lipids and lipid nanoparticle formulations for nucleic acid delivery
EP3373965A1 (en)2015-11-092018-09-19CureVac AGRotavirus vaccines
DK3319622T3 (en)2015-12-222020-05-04Curevac Ag PROCEDURE FOR PREPARING RNA MOLECULE COMPOSITIONS
WO2017109161A1 (en)2015-12-232017-06-29Curevac AgMethod of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
US11723967B2 (en)2016-02-172023-08-15CureVac SEZika virus vaccine
BR112018017307A2 (en)*2016-02-252019-01-08Univ Pennsylvania isolated nucleic acid molecule, composition, and methods for inducing an immune response against a Zika virus, for treating an individual, and for preventing a Zika virus infection
EP3423595A1 (en)2016-03-032019-01-09CureVac AGRna analysis by total hydrolysis
WO2017186928A1 (en)2016-04-292017-11-02Curevac AgRna encoding an antibody
EP3452101A2 (en)2016-05-042019-03-13CureVac AGRna encoding a therapeutic protein
EP4477662A3 (en)2016-05-042025-03-19CureVac SENucleic acid molecules and uses thereof
WO2017214596A1 (en)*2016-06-092017-12-14Beth Israel Deaconess Medical Center, Inc.Compositions and methods for preventing and treating zika virus infection
CA3023174A1 (en)2016-06-092017-12-14Curevac AgHybrid carriers for nucleic acid cargo
WO2018029452A1 (en)*2016-08-082018-02-15The Secretary Of State For HealthFlavivirus diagnostic assay
JP2019533477A (en)2016-09-162019-11-21ペブル ラブス A novel paratransgenic system for biological control of spread mosquitoes
US11279923B2 (en)2016-11-282022-03-22Curevac AgMethod for purifying RNA
WO2018102659A1 (en)*2016-12-012018-06-07The Trustees Of Columbia University In The City Of New YorkSerological assay for zika virus infection
US11464836B2 (en)2016-12-082022-10-11Curevac AgRNA for treatment or prophylaxis of a liver disease
US11542490B2 (en)2016-12-082023-01-03CureVac SERNAs for wound healing
EP3558354A1 (en)2016-12-232019-10-30CureVac AGLassa virus vaccine
EP3558356A2 (en)2016-12-232019-10-30CureVac AGMers coronavirus vaccine
WO2018115507A2 (en)2016-12-232018-06-28Curevac AgHenipavirus vaccine
JP7317715B2 (en)*2017-01-112023-07-31ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Nucleoside modified RNA for inducing immune response against Zika virus
WO2018151816A1 (en)*2017-02-162018-08-23Modernatx, Inc.High potency immunogenic compositions
US11739335B2 (en)2017-03-242023-08-29CureVac SENucleic acids encoding CRISPR-associated proteins and uses thereof
US11357856B2 (en)2017-04-132022-06-14Acuitas Therapeutics, Inc.Lipids for delivery of active agents
US11660332B2 (en)2017-04-272023-05-30The Trustees Of The University Of PennsylvaniaNucleoside-modified mRNA-lipid nanoparticle lineage vaccine for hepatitis C virus
AU2018256877B2 (en)2017-04-282022-06-02Acuitas Therapeutics, Inc.Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids
US12297489B2 (en)2017-05-172025-05-13CureVac Manufacturing GmbHMethod for determining at least one quality parameter of an RNA sample
EP4494652A3 (en)2017-07-042025-05-14CureVac SECancer rna-vaccine
JP7355731B2 (en)2017-08-162023-10-03アクイタス セラピューティクス インコーポレイテッド Lipids for use in lipid nanoparticle formulations
US11542225B2 (en)2017-08-172023-01-03Acuitas Therapeutics, Inc.Lipids for use in lipid nanoparticle formulations
ES2997124T3 (en)2017-08-172025-02-14Acuitas Therapeutics IncLipids for use in lipid nanoparticle formulations
US11524932B2 (en)2017-08-172022-12-13Acuitas Therapeutics, Inc.Lipids for use in lipid nanoparticle formulations
WO2019038332A1 (en)2017-08-222019-02-28Curevac AgBunyavirales vaccine
MA50253A (en)2017-09-142020-07-22Modernatx Inc ZIKA VIRUS RNA VACCINES
BR112020005565A2 (en)*2017-09-212020-10-06Emergex Vaccines Holding Limited class i mhc-associated peptides for prevention and treatment of zika virus
RU2020115287A (en)2017-10-192021-11-19Куревак Аг NEW MOLECULES OF ARTIFICIAL NUCLEIC ACIDS
EP3703739A2 (en)2017-11-032020-09-09Takeda Vaccines, Inc.Zika vaccines and immunogenic compositions, and methods of using the same
SG11202003247RA (en)2017-11-082020-05-28Curevac AgRna sequence adaptation
WO2019092142A1 (en)*2017-11-092019-05-16Institut PasteurA zika virus chimeric polyepitope comprising non-structural proteins and its use in an immunogenic composition
US11739348B2 (en)2017-11-102023-08-29The Research Institute At Nationwide Children's HospitalRecombinant vectors encoding Zika virus protein subunits
US20210403879A1 (en)2017-11-302021-12-30Takeda Vaccines, Inc.Method for inactivating zika virus and related methods
WO2019115635A1 (en)2017-12-132019-06-20Curevac AgFlavivirus vaccine
CN111511928A (en)2017-12-212020-08-07库瑞瓦格股份公司 Linear double-stranded DNA coupled to a single support or tag and method for preparing the linear double-stranded DNA
BR112020012307A2 (en)*2017-12-212020-11-24PEPperPRINT GmbH ns2b as a marker for zica virus infections
CN108210921A (en)*2017-12-292018-06-29广州恩宝生物医药科技有限公司A kind of zika virus vaccine and preparation method thereof
WO2019135086A1 (en)2018-01-062019-07-11Emergex Vaccines Holding LimitedMhc class i associated peptides for prevention and treatment of multiple flavi virus
CN108484737B (en)*2018-02-092021-04-23四川农业大学 Expression method, product and application of Tembusu virus non-structural protein NS4B truncated protein
JP2021519762A (en)*2018-03-292021-08-12イマージェクス ヴァクシンズ ホールディング リミテッドEmergex Vaccines Holding Limited Vaccine composition
CN112292395A (en)2018-04-172021-01-29库瑞瓦格股份公司 Novel RSV RNA molecules and compositions for vaccination
KR20210027368A (en)2018-06-282021-03-10큐어백 아게 R&A bioreactor for in vitro transcription
WO2020019024A1 (en)*2018-07-232020-01-30The University Of AdelaideZika virus vaccine
US11702453B2 (en)2018-08-212023-07-18Regents Of The University Of MichiganMaterials and methods for inhibiting flavivirus infection
EP3852911B1 (en)2018-09-212025-01-22Acuitas Therapeutics, Inc.Systems and methods for manufacturing lipid nanoparticles and liposomes
US12070495B2 (en)2019-03-152024-08-27Modernatx, Inc.HIV RNA vaccines
US20220168412A1 (en)*2019-04-102022-06-02Katholieke Universiteit LeuvenChimeric Zika-Japanese Encephalitis Virus
CN114901360A (en)2019-12-202022-08-12库瑞瓦格股份公司Novel lipid nanoparticles for delivery of nucleic acids
US11241493B2 (en)2020-02-042022-02-08Curevac AgCoronavirus vaccine
US12194089B2 (en)2020-02-042025-01-14CureVac SECoronavirus vaccine
US20230065376A1 (en)*2020-02-052023-03-02New York Blood Center, Inc.Zika virus immunogenic compositions
AU2021229452A1 (en)*2020-03-032022-09-29Mayo Foundation For Medical Education And ResearchZika virus polypeptides
CN111514286B (en)*2020-04-012022-03-08中国科学院过程工程研究所Zika virus E protein conjugate vaccine and preparation method thereof
WO2021262659A1 (en)*2020-06-222021-12-30University Of ConnecticutFlavivirus signal peptides, vaccine constructs, and methods therefor
CN116096702A (en)2020-07-162023-05-09爱康泰生治疗公司 Cationic Lipids for Lipid Nanoparticles
KR20230164648A (en)2020-12-222023-12-04큐어백 에스이 RNA vaccines against SARS-CoV-2 variants
CU24751B1 (en)*2021-07-282025-06-11Ct Ingenieria Genetica Biotecnologia Recombinant antigen for the induction of immune response against the Zika virus
US20240335525A1 (en)2021-08-112024-10-10Sanofi Pasteur Inc.Truncated influenza neuraminidase and methods of using the same
WO2023031394A1 (en)2021-09-032023-03-09CureVac SENovel lipid nanoparticles for delivery of nucleic acids
MX2024002725A (en)2021-09-032024-03-15CureVac SENovel lipid nanoparticles for delivery of nucleic acids comprising phosphatidylserine.
CN118647600A (en)2021-12-162024-09-13爱康泰生治疗公司 Lipids for lipid nanoparticle formulation
EP4608442A1 (en)2022-10-282025-09-03GlaxoSmithKline Biologicals S.A.Nucleic acid based vaccine
WO2024184500A1 (en)2023-03-082024-09-12CureVac SENovel lipid nanoparticle formulations for delivery of nucleic acids
CN116855514A (en)*2023-07-142023-10-10中国科学院微生物研究所mRNA encoding Zika virus antigen peptide, mRNA vaccine based on same and preparation method thereof
WO2025043010A1 (en)*2023-08-232025-02-27Vyro Bio Inc.Nucleic acid compositions for the generation of a zika virus-like particle
CN120241984A (en)*2025-06-042025-07-04中国食品药品检定研究院 A two-component Zika mRNA vaccine and its use

Family Cites Families (119)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
EP1903054A3 (en)2001-06-052008-07-23CureVac GmbHPharmaceutical compound containing a stabilised mRNA which is optimised for translation in its coded areas
DE10162480A1 (en)2001-12-192003-08-07Ingmar Hoerr The application of mRNA for use as a therapeutic agent against tumor diseases
DE10229872A1 (en)2002-07-032004-01-29Curevac Gmbh Immune stimulation through chemically modified RNA
DE10335833A1 (en)2003-08-052005-03-03Curevac Gmbh Transfection of blood cells with mRNA for immune stimulation and gene therapy
DE102004042546A1 (en)2004-09-022006-03-09Curevac Gmbh Combination therapy for immune stimulation
DE102005023170A1 (en)2005-05-192006-11-23Curevac Gmbh Optimized formulation for mRNA
DE102006035618A1 (en)2006-07-312008-02-07Curevac GmbhNew nucleic acid useful as immuno-stimulating adjuvant for manufacture of a composition for treatment of cancer diseases e.g. colon carcinomas and infectious diseases e.g. influenza and malaria
DE102006061015A1 (en)2006-12-222008-06-26Curevac Gmbh Process for the purification of RNA on a preparative scale by HPLC
DE102007001370A1 (en)2007-01-092008-07-10Curevac Gmbh RNA-encoded antibodies
WO2009030254A1 (en)2007-09-042009-03-12Curevac GmbhComplexes of rna and cationic peptides for transfection and for immunostimulation
WO2009046739A1 (en)2007-10-092009-04-16Curevac GmbhComposition for treating prostate cancer (pca)
WO2009046738A1 (en)2007-10-092009-04-16Curevac GmbhComposition for treating lung cancer, particularly of non-small lung cancers (nsclc)
RU2545701C2 (en)2008-01-312015-04-10Куревак ГмбхNUCLEIC ACIDS OF FORMULA (I) (NuGlXmGnNv)a AND DERIVATIVES THEREOF AS IMMUNOSTIMULATING AGENTS/ADJUVANTS
WO2010037408A1 (en)2008-09-302010-04-08Curevac GmbhComposition comprising a complexed (m)rna and a naked mrna for providing or enhancing an immunostimulatory response in a mammal and uses thereof
US20110053829A1 (en)2009-09-032011-03-03Curevac GmbhDisulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
US8691961B1 (en)*2009-11-092014-04-08Integral Molecular, Inc.Flavivirus reporter virus and methods of making and using the same
WO2011069529A1 (en)2009-12-092011-06-16Curevac GmbhMannose-containing solution for lyophilization, transfection and/or injection of nucleic acids
CA2801523C (en)2010-07-302021-08-03Curevac GmbhComplexation of nucleic acids with disulfide-crosslinked cationic components for transfection and immunostimulation
WO2012019630A1 (en)2010-08-132012-02-16Curevac GmbhNucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded protein
WO2012089225A1 (en)2010-12-292012-07-05Curevac GmbhCombination of vaccination and inhibition of mhc class i restricted antigen presentation
WO2012116715A1 (en)2011-03-022012-09-07Curevac GmbhVaccination in newborns and infants
WO2012113413A1 (en)2011-02-212012-08-30Curevac GmbhVaccine composition comprising complexed immunostimulatory nucleic acids and antigens packaged with disulfide-linked polyethyleneglycol/peptide conjugates
WO2012116714A1 (en)2011-03-022012-09-07Curevac GmbhVaccination in elderly patients
WO2013113325A1 (en)2012-01-312013-08-08Curevac GmbhNegatively charged nucleic acid comprising complexes for immunostimulation
WO2013113326A1 (en)2012-01-312013-08-08Curevac GmbhPharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
EP2623121A1 (en)2012-01-312013-08-07Bayer Innovation GmbHPharmaceutical composition comprising a polymeric carrier cargo complex and an antigen
WO2013120500A1 (en)2012-02-152013-08-22Curevac GmbhNucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen
WO2013120499A1 (en)2012-02-152013-08-22Curevac GmbhNucleic acid comprising or coding for a histone stem-loop and a poly (a) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigen
WO2013120498A1 (en)2012-02-152013-08-22Curevac GmbhNucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
WO2013120497A1 (en)2012-02-152013-08-22Curevac GmbhNucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein
SG10201607966UA (en)2012-03-272016-11-29Curevac AgArtificial nucleic acid molecules comprising a 5'top utr
CA2859452C (en)2012-03-272021-12-21Curevac GmbhArtificial nucleic acid molecules for improved protein or peptide expression
AU2013242403B2 (en)2012-03-272018-10-18Curevac AgArtificial nucleic acid molecules
ES2719598T3 (en)2012-05-252019-07-11Curevac Ag Reversible immobilization and / or controlled release of nucleic acids contained in nanoparticles by polymeric coatings (biodegradable)
CA2897858A1 (en)2013-02-222014-08-28Curevac GmbhCombination of vaccination and inhibition of the pd-1 pathway
SG11201510746WA (en)2013-08-212016-03-30Curevac AgRespiratory syncytial virus (rsv) vaccine
EA037217B1 (en)2013-08-212021-02-20Куревак АгComposition and vaccine for treating lung cancer
AU2014310933B2 (en)2013-08-212020-05-14CureVac SEMethod for increasing expression of RNA-encoded proteins
AU2014310935B2 (en)2013-08-212019-11-21CureVac SECombination vaccine
CA2915712A1 (en)2013-08-212015-02-26Margit SCHNEERabies vaccine
WO2015024664A1 (en)2013-08-212015-02-26Curevac GmbhComposition and vaccine for treating prostate cancer
ES2806575T3 (en)2013-11-012021-02-18Curevac Ag Modified RNA with decreased immunostimulatory properties
MX372790B (en)2013-12-302020-07-03CureVac SE ARTIFICIAL NUCLEIC ACID MOLECULES.
JP6584414B2 (en)2013-12-302019-10-02キュアバック アーゲー Artificial nucleic acid molecule
AU2014375404C1 (en)2013-12-302020-11-19CureVac Manufacturing GmbHMethods for RNA analysis
EP3116535B1 (en)2014-03-122019-08-07CureVac AGCombination of vaccination and ox40 agonists
WO2015149944A2 (en)2014-04-012015-10-08Curevac GmbhPolymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant
AU2015273933B2 (en)2014-06-102021-02-11CureVac Manufacturing GmbHMethods and means for enhancing RNA production
EP3708668B1 (en)2014-12-122022-07-27CureVac AGArtificial nucleic acid molecules for improved protein expression
EP3233113A1 (en)2014-12-162017-10-25CureVac AGEbolavirus and marburgvirus vaccines
WO2016107877A1 (en)2014-12-302016-07-07Curevac AgArtificial nucleic acid molecules
WO2016165825A1 (en)2015-04-132016-10-20Curevac AgMethod for producing rna compositions
EP3283125B1 (en)2015-04-172021-12-29CureVac Real Estate GmbHLyophilization of rna
WO2016170176A1 (en)2015-04-222016-10-27Curevac AgRna containing composition for treatment of tumor diseases
WO2016174227A1 (en)2015-04-302016-11-03Curevac AgMethod for in vitro transcription using an immobilized restriction enzyme
SG11201708867UA (en)2015-04-302017-11-29Curevac AgImmobilized poly(n)polymerase
WO2016180430A1 (en)2015-05-082016-11-17Curevac AgMethod for producing rna
JP6893177B2 (en)2015-05-152021-06-23キュアバック アーゲー PRIME-BOOST REGIMENS containing administration of at least one mRNA construct
SG10201910431RA (en)2015-05-202020-01-30Curevac AgDry powder composition comprising long-chain rna
US10729654B2 (en)2015-05-202020-08-04Curevac AgDry powder composition comprising long-chain RNA
DE202016009003U1 (en)2015-05-292021-05-28Curevac Real Estate Gmbh Composition comprising in vitro transcribed RNA obtainable by a method for the production and purification of RNA with at least one step with a tangential flow filtration
WO2016193226A1 (en)2015-05-292016-12-08Curevac AgMethod for adding cap structures to rna using immobilized enzymes
EP3310384A1 (en)2015-06-172018-04-25CureVac AGVaccine composition
WO2016210127A1 (en)2015-06-252016-12-29Technovax, Inc.Flavivirus and alphavirus virus-like particles (vlps)
WO2017001058A1 (en)2015-07-012017-01-05Curevac AgMethod for analysis of an rna molecule
US10501768B2 (en)2015-07-132019-12-10Curevac AgMethod of producing RNA from circular DNA and corresponding template DNA
ES2937963T3 (en)*2015-07-212023-04-03Modernatx Inc Infectious disease vaccines
EP3331555A1 (en)2015-08-052018-06-13CureVac AGEpidermal mrna vaccine
EP3699288A1 (en)2015-08-072020-08-26CureVac AGProcess for the in vivo production of rna in a host cell
WO2017025447A1 (en)2015-08-102017-02-16Curevac AgMethod of increasing the replication of a circular dna molecule
ES2924739T3 (en)2015-08-282022-10-10Curevac Ag artificial nucleic acid molecules
WO2017064146A1 (en)2015-10-122017-04-20Curevac AgAutomated method for isolation, selection and/or detection of microorganisms or cells comprised in a solution
EP3364950A4 (en)*2015-10-222019-10-23ModernaTX, Inc. VACCINES AGAINST TROPICAL DISEASES
EP3373965A1 (en)2015-11-092018-09-19CureVac AGRotavirus vaccines
WO2017081082A2 (en)2015-11-092017-05-18Curevac AgOptimized nucleic acid molecules
WO2017108087A1 (en)2015-12-212017-06-29Curevac AgInlay for a culture plate and corresponding method for preparing a culture plate system with such inlay
DK3319622T3 (en)2015-12-222020-05-04Curevac Ag PROCEDURE FOR PREPARING RNA MOLECULE COMPOSITIONS
WO2017109161A1 (en)2015-12-232017-06-29Curevac AgMethod of rna in vitro transcription using a buffer containing a dicarboxylic acid or tricarboxylic acid or a salt thereof
WO2017137095A1 (en)2016-02-122017-08-17Curevac AgMethod for analyzing rna
US20190049414A1 (en)2016-02-152019-02-14Curevac AgMethod for analyzing by-products of rna in vitro transcription
US11723967B2 (en)2016-02-172023-08-15CureVac SEZika virus vaccine
EP3423595A1 (en)2016-03-032019-01-09CureVac AGRna analysis by total hydrolysis
WO2017161151A1 (en)*2016-03-162017-09-21Novavax, Inc.Vaccine compositions containing modified zika virus antigens
EP3433361A1 (en)2016-03-242019-01-30CureVac AGImmobilized inorganic pyrophosphatase (ppase)
EP3777881A1 (en)2016-04-222021-02-17CureVac AGRna encoding a tumor antigen
WO2017186928A1 (en)2016-04-292017-11-02Curevac AgRna encoding an antibody
WO2017191258A1 (en)2016-05-042017-11-09Curevac AgInfluenza mrna vaccines
EP3452101A2 (en)2016-05-042019-03-13CureVac AGRna encoding a therapeutic protein
US20180126003A1 (en)2016-05-042018-05-10Curevac AgNew targets for rna therapeutics
EP4477662A3 (en)2016-05-042025-03-19CureVac SENucleic acid molecules and uses thereof
WO2017203008A1 (en)2016-05-252017-11-30Curevac AgNovel biomarkers
EP3468612A1 (en)2016-06-092019-04-17CureVac AGHybrid carriers for nucleic acid cargo
CA3023174A1 (en)2016-06-092017-12-14Curevac AgHybrid carriers for nucleic acid cargo
US20190336611A1 (en)2016-06-092019-11-07Curevac AgHybrid carriers for nucleic acid cargo
WO2017212007A1 (en)2016-06-092017-12-14Curevac AgCationic carriers for nucleic acid delivery
US20190185859A1 (en)2016-08-192019-06-20Curevac AgRna for cancer therapy
US10898566B2 (en)*2016-09-192021-01-26The United States Of America, As Represented By The Secretary, Department Of Health And Human ServicesZika virus vaccines
KR20240150810A (en)2016-10-262024-10-16큐어백 에스이Lipid nanoparticle mrna vaccines
US11279923B2 (en)2016-11-282022-03-22Curevac AgMethod for purifying RNA
US11542490B2 (en)2016-12-082023-01-03CureVac SERNAs for wound healing
US11464836B2 (en)2016-12-082022-10-11Curevac AgRNA for treatment or prophylaxis of a liver disease
WO2018115507A2 (en)2016-12-232018-06-28Curevac AgHenipavirus vaccine
EP3558354A1 (en)2016-12-232019-10-30CureVac AGLassa virus vaccine
EP3558356A2 (en)2016-12-232019-10-30CureVac AGMers coronavirus vaccine
JP7317715B2 (en)2017-01-112023-07-31ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Nucleoside modified RNA for inducing immune response against Zika virus
CA3050614A1 (en)2017-03-172018-09-20Curevac AgRna vaccine and immune checkpoint inhibitors for combined anticancer therapy
US11739335B2 (en)2017-03-242023-08-29CureVac SENucleic acids encoding CRISPR-associated proteins and uses thereof
EP4494652A3 (en)2017-07-042025-05-14CureVac SECancer rna-vaccine
WO2019038332A1 (en)2017-08-222019-02-28Curevac AgBunyavirales vaccine
WO2019115635A1 (en)2017-12-132019-06-20Curevac AgFlavivirus vaccine
CN111511928A (en)2017-12-212020-08-07库瑞瓦格股份公司 Linear double-stranded DNA coupled to a single support or tag and method for preparing the linear double-stranded DNA
US20210361761A1 (en)2018-04-052021-11-25Curevac AgNovel yellow fever nucleic acid molecules for vaccination
CN112292395A (en)2018-04-172021-01-29库瑞瓦格股份公司 Novel RSV RNA molecules and compositions for vaccination
KR20210027368A (en)2018-06-282021-03-10큐어백 아게 R&A bioreactor for in vitro transcription
CA3122645A1 (en)2018-12-212020-06-25Curevac AgMethods for rna analysis
EP3897702A2 (en)2018-12-212021-10-27CureVac AGRna for malaria vaccines
CA3164395A1 (en)2020-01-112021-07-15Lyndsey M. LINKEA microbial system for production and delivery of eukaryote-translatable mrna to eukarya
US11241493B2 (en)2020-02-042022-02-08Curevac AgCoronavirus vaccine
WO2021211343A1 (en)2020-04-132021-10-21Modernatx, Inc.Zika virus mrna vaccines

Also Published As

Publication numberPublication date
BR112018016755A2 (en)2018-12-26
MX2018014573A (en)2019-09-04
WO2017140905A1 (en)2017-08-24
EP3416683A1 (en)2018-12-26
SG10201913630YA (en)2020-03-30
US20240024453A1 (en)2024-01-25
US11723967B2 (en)2023-08-15
MX2018009917A (en)2019-08-14
US20210205434A1 (en)2021-07-08

Similar Documents

PublicationPublication DateTitle
SG11201806340YA (en)Zika virus vaccine
SG11201906297QA (en)Nucleic acids encoding crispr-associated proteins and uses thereof
SG11201811432WA (en)Rna for cancer therapy
SG11201805229YA (en)Means and methods for treating hbv
SG11201903021WA (en)Anti-human 4-1 bb antibodies and use thereof
SG11201903454VA (en)Immunologically discernible cell surface variants for use in cell therapy
SG11201906431UA (en)Method for the treatment of thromboembolism
SG11201810594RA (en)Nucleic acid molecules for reduction of papd5 or papd7 mrna for treating hepatitis b infection
SG11201811431VA (en)Multispecific antibodies against cd40 and cd137
SG11201407512VA (en)High-concentration monoclonal antibody formulations
SG11201809912UA (en)Hybrid carriers for nucleic acid cargo
SG11201806863WA (en)Tetracyclic pyridone compounds as antivirals
SG11201805570WA (en)Systems and methods for long term transdermal administration
SG11201809879WA (en)Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201901961SA (en)Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
SG11201807913XA (en)Stabilized soluble pre-fusion rsv f proteins
SG11201408405WA (en)Engineered three-dimensional connective tissue constructs and methods of making the same
SG11201811230RA (en)Compositions and methods for reducing ocular neovascularization
SG11201808222RA (en)Methods of treatment of cholestatic diseases
SG11201807041PA (en)Improved preparations of adult liver progenitor cells
SG11201900021PA (en)Methods and compositions for the treatment of cancer
SG11201900845YA (en)Uses of il-13 antagonists for treating atopic dermatitis
SG11201907196YA (en)Composition and methods for preventing radiation injury and promoting tissue regeneration
SG11201805001UA (en)Method of treating influenza a
SG11201808592PA (en)Method for selection of high m6p recombinant proteins

[8]ページ先頭

©2009-2025 Movatter.jp